CN108409863B - 抗凝血因子xi抗体 - Google Patents

抗凝血因子xi抗体 Download PDF

Info

Publication number
CN108409863B
CN108409863B CN201710073984.XA CN201710073984A CN108409863B CN 108409863 B CN108409863 B CN 108409863B CN 201710073984 A CN201710073984 A CN 201710073984A CN 108409863 B CN108409863 B CN 108409863B
Authority
CN
China
Prior art keywords
antibody
antibodies
prt
fxi
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710073984.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108409863A (zh
Inventor
王文义
于泉
刘小五
徐立忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Benemae Pharmaceutical Corp
Original Assignee
Shanghai Benemae Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201710073984.XA priority Critical patent/CN108409863B/zh
Application filed by Shanghai Benemae Pharmaceutical Corp filed Critical Shanghai Benemae Pharmaceutical Corp
Priority to BR112019016300-0A priority patent/BR112019016300A2/pt
Priority to KR1020197025752A priority patent/KR102690437B1/ko
Priority to AU2017397778A priority patent/AU2017397778B2/en
Priority to EP17895532.4A priority patent/EP3581587B1/en
Priority to PCT/CN2017/119856 priority patent/WO2018145533A1/zh
Priority to CA3054322A priority patent/CA3054322A1/en
Priority to RU2019128423A priority patent/RU2800719C2/ru
Priority to JP2019543277A priority patent/JP7271430B2/ja
Priority to MX2019009500A priority patent/MX2019009500A/es
Publication of CN108409863A publication Critical patent/CN108409863A/zh
Priority to US16/537,427 priority patent/US11958911B2/en
Application granted granted Critical
Publication of CN108409863B publication Critical patent/CN108409863B/zh
Priority to AU2025203303A priority patent/AU2025203303A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710073984.XA 2017-02-10 2017-02-10 抗凝血因子xi抗体 Active CN108409863B (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201710073984.XA CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体
JP2019543277A JP7271430B2 (ja) 2017-02-10 2017-12-29 抗ｘｉ因子抗体
AU2017397778A AU2017397778B2 (en) 2017-02-10 2017-12-29 Anti-coagulation factor XI antibody
EP17895532.4A EP3581587B1 (en) 2017-02-10 2017-12-29 Anti-coagulation factor xi antibody
PCT/CN2017/119856 WO2018145533A1 (zh) 2017-02-10 2017-12-29 抗凝血因子xi抗体
CA3054322A CA3054322A1 (en) 2017-02-10 2017-12-29 Anti-coagulation factor xi antibodies
BR112019016300-0A BR112019016300A2 (pt) 2017-02-10 2017-12-29 ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO
KR1020197025752A KR102690437B1 (ko) 2017-02-10 2017-12-29 항-응고 인자 xi 항체
MX2019009500A MX2019009500A (es) 2017-02-10 2017-12-29 Anticuerpos anti factor de coagulación xi.
RU2019128423A RU2800719C2 (ru) 2017-02-10 2017-12-29 Антитела к фактору xi
US16/537,427 US11958911B2 (en) 2017-02-10 2019-08-09 Anti-coagulation factor XI antibody
AU2025203303A AU2025203303A1 (en) 2017-02-10 2025-05-08 Anti-coagulation factor XI antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710073984.XA CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体

Publications (2)

Publication Number Publication Date
CN108409863A CN108409863A (zh) 2018-08-17
CN108409863B true CN108409863B (zh) 2023-09-26

Family

ID=63107934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710073984.XA Active CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体

Country Status (9)

Country Link
EP (1) EP3581587B1 (https=)
JP (1) JP7271430B2 (https=)
KR (1) KR102690437B1 (https=)
CN (1) CN108409863B (https=)
AU (2) AU2017397778B2 (https=)
BR (1) BR112019016300A2 (https=)
CA (1) CA3054322A1 (https=)
MX (1) MX2019009500A (https=)
WO (1) WO2018145533A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CA3108708A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
CA3125303A1 (en) * 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof
JP7650807B2 (ja) * 2019-04-16 2025-03-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN110498839A (zh) * 2019-09-19 2019-11-26 河南省农业科学院 氟罗沙星单链抗体关键多肽序列及应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN116589588B (zh) * 2023-04-14 2023-12-22 北京基科晟斯医药科技有限公司 结合凝血因子x的抗体
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03228690A (ja) * 1990-02-02 1991-10-09 Dai Ichi Pure Chem Co Ltd 血液凝固第１０３因子に対するモノクロナール抗体
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
HK1207091A1 (en) * 2012-05-10 2016-01-22 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2017015619A1 (en) * 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316574T3 (es) * 2001-06-12 2009-04-16 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Anticuerpo de tipo humano contra el factor viii de la coagulacion sanguinea.
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
US8388959B2 (en) * 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03228690A (ja) * 1990-02-02 1991-10-09 Dai Ichi Pure Chem Co Ltd 血液凝固第１０３因子に対するモノクロナール抗体
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
HK1207091A1 (en) * 2012-05-10 2016-01-22 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2017015619A1 (en) * 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis;C Zhong;《Journal of Thrombosis and Haemostasis》;20161224;第15卷(第1期);第122-130页 *
Factor XIa inhibitors: A review of the patent literature;Rami A Al-Horani;《Expert Opinion on Therapeutic Patents》;20160225;第26卷(第3期);第323-345页 *
Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years;G Ling;《Haemophilia：the offical journal of the World Federation of Hemophilia》;20151209;第22卷(第3期);第411-418 *

Also Published As

Publication number Publication date
JP2020507578A (ja) 2020-03-12
JP7271430B2 (ja) 2023-05-11
AU2025203303A1 (en) 2025-05-29
KR20190116990A (ko) 2019-10-15
AU2017397778B2 (en) 2025-03-06
EP3581587A1 (en) 2019-12-18
AU2017397778A1 (en) 2019-10-03
RU2019128423A3 (https=) 2021-03-19
CN108409863A (zh) 2018-08-17
RU2019128423A (ru) 2021-03-10
WO2018145533A1 (zh) 2018-08-16
EP3581587A4 (en) 2021-03-31
MX2019009500A (es) 2020-01-30
BR112019016300A2 (pt) 2020-06-16
CA3054322A1 (en) 2018-08-16
KR102690437B1 (ko) 2024-07-30
EP3581587B1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
CN108409863B (zh) 抗凝血因子xi抗体
AU2017325240B9 (en) Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
RU2731713C2 (ru) Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях
JP2020510081A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
CN113272326B (zh) 治疗嗜中性病症的方法
CN113227150B (zh) 抗凝血因子xi抗体
KR20240135884A (ko) Tfpi 길항제의 투여량 섭생법
JP7722991B2 (ja) 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
US20230039165A1 (en) Igfbp3 antibodies and therapeutic uses thereof
US12583929B2 (en) Method of treating acute respiratory distress syndrome
RU2800719C2 (ru) Антитела к фактору xi
HK40010556A (en) Anti-coagulation factor xi antibody
HK40075244B (zh) 抗凝血因子xi抗体
HK40097171A (zh) 抗凝血因子xi抗体
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
CA3035327C (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
HK40075244A (en) Anticoagulant factor xi antibodies
HK40057273B (zh) 抗凝血因子xi抗体
HK40075243B (zh) 抗凝血因子xi抗体
HK40057273A (en) Anti-factor xi antibodies
TW200944230A (en) Anti-VEGF monoclonal antibody
HK1190410B (en) Antibodies that bind tgf-alpha and epiregulin
HK1190410A1 (en) Antibodies that bind tgf-alpha and epiregulin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information

Inventor after: Wang Wenyi

Inventor after: Yu Quan

Inventor after: Liu Xiaowu

Inventor after: Xu Lizhong

Inventor before: Wang Wenyi

Inventor before: Yu Quan

Inventor before: Liu Xiaowu

CB03 Change of inventor or designer information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment